Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC
CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Acceptance for Fluzoparib in First‑Line Therapy of DNA‑Repair‑Defect Positive mCRPC

Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer
CompanyDrug

Nanjing Leads Biolabs Announces First‑Patient Dose of LBL‑024, a Novel Bispecific Antibody for Biliary Tract Cancer

Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025
CompanyDrug

Eisai and Merck Present 5‑Year Survival Data for Lenvatinib‑Pembrolizumab in Advanced Endometrial Carcinoma at ESMO 2025

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline
CompanyDeals

PolyMed Biopharmaceuticals Completes Pre‑A++ Funding Round Led by Caleb Capital, Fuels PROTAC‑Focused Pipeline

NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5
Policy / Regulatory

NMPA Releases Draft Measures on Drug Quality Sampling, Seeks Public Comments by Nov 5

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia
Policy / Regulatory

Novartis Asciminib Enters China’s SPARK Program for Pediatric Chronic Myeloid Leukemia

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion
Others

WuXi AppTec Sells WuXi Clinical and MedKey to Hillhouse for RMB 2.8 Billion

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion
Company

Wuxi Apptec Reports 15.3 % YoY Revenue Growth in Q3 2025, Net Profit Hits RMB 4.22 Billion

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression
CompanyDrug

Grand Pharma Launches GPN00884 Clinical Trial to Tackle Pediatric Myopia Progression

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
CompanyDeals

Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access
CompanyDeals

Eli Lilly to Acquire Adverum Biotechnologies for Up to USD 261.7m for Ixo-vec Access

Alphamab Oncology's JSKN003 Approved for Phase III Trial in HER2-Positive CRC
CompanyDrug

Alphamab Oncology’s JSKN003 Approved for Phase III Trial in HER2-Positive CRC